Jing Zhou1, Yang Lin1, Xiuhua Kang1, Zhicheng Liu1, Wei Zhang2, Fei Xu3. 1. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, No. 17, Yongwaizheng Street, Nanchang, 330006, Jiangxi Province, China. 2. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, No. 17, Yongwaizheng Street, Nanchang, 330006, Jiangxi Province, China. zhangweiliuxing1@163.com. 3. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, No. 17, Yongwaizheng Street, Nanchang, 330006, Jiangxi Province, China. drFeiXuuue@163.com.
Abstract
BACKGROUND: Previous reports have identified that human bone marrow mesenchymal stem cell-derived extracellular vesicles (BMSC-EVs) with their cargo microRNAs (miRNAs) are a promising therapeutic approach for the treatment of idiopathic pulmonary fibrosis (IPF). Therefore, we explored whether delivery of microRNA-186 (miR-186), a downregulated miRNA in IPF, by BMSC EVs could interfere with the progression of IPF in a murine model. METHODS: In a co-culture system, we assessed whether BMSC-EVs modulated the activation of fibroblasts. We established a mouse model of PF to evaluate the in vivo therapeutic effects of BMSC-EVs and determined miR-186 expression in BMSC-EVs by polymerase chain reaction. Using a loss-of-function approach, we examined how miR-186 delivered by BMSC-EVs affected fibroblasts. The putative relationship between miR-186 and SRY-related HMG box transcription factor 4 (SOX4) was tested using luciferase assay. Next, we investigated whether EV-miR-186 affected fibroblast activation and PF by targeting SOX4 and its downstream gene, Dickkopf-1 (DKK1). RESULTS: BMSC-EVs suppressed lung fibroblast activation and delayed IPF progression in mice. miR-186 was downregulated in IPF but enriched in the BMSC-EVs. miR-186 delivered by BMSC-EVs could suppress fibroblast activation. Furthermore, miR-186 reduced the expression of SOX4, a target gene of miR-186, and hence suppressed the expression of DKK1. Finally, EV-delivered miR-186 impaired fibroblast activation and alleviated PF via downregulation of SOX4 and DKK1. CONCLUSION: In conclusion, miR-186 delivered by BMSC-EVs suppressed SOX4 and DKK1 expression, thereby blocking fibroblast activation and ameliorating IPF, thus presenting a novel therapeutic target for IPF.
BACKGROUND: Previous reports have identified that human bone marrow mesenchymal stem cell-derived extracellular vesicles (BMSC-EVs) with their cargo microRNAs (miRNAs) are a promising therapeutic approach for the treatment of idiopathic pulmonary fibrosis (IPF). Therefore, we explored whether delivery of microRNA-186 (miR-186), a downregulated miRNA in IPF, by BMSC EVs could interfere with the progression of IPF in a murine model. METHODS: In a co-culture system, we assessed whether BMSC-EVs modulated the activation of fibroblasts. We established a mouse model of PF to evaluate the in vivo therapeutic effects of BMSC-EVs and determined miR-186 expression in BMSC-EVs by polymerase chain reaction. Using a loss-of-function approach, we examined how miR-186 delivered by BMSC-EVs affected fibroblasts. The putative relationship between miR-186 and SRY-related HMG box transcription factor 4 (SOX4) was tested using luciferase assay. Next, we investigated whether EV-miR-186 affected fibroblast activation and PF by targeting SOX4 and its downstream gene, Dickkopf-1 (DKK1). RESULTS: BMSC-EVs suppressed lung fibroblast activation and delayed IPF progression in mice. miR-186 was downregulated in IPF but enriched in the BMSC-EVs. miR-186 delivered by BMSC-EVs could suppress fibroblast activation. Furthermore, miR-186 reduced the expression of SOX4, a target gene of miR-186, and hence suppressed the expression of DKK1. Finally, EV-delivered miR-186 impaired fibroblast activation and alleviated PF via downregulation of SOX4 and DKK1. CONCLUSION: In conclusion, miR-186 delivered by BMSC-EVs suppressed SOX4 and DKK1 expression, thereby blocking fibroblast activation and ameliorating IPF, thus presenting a novel therapeutic target for IPF.
Entities:
Keywords:
Extracellular vesicles; Fibroblasts; Human bone marrow mesenchymal stem cells; Idiopathic pulmonary fibrosis; SRY-related HMG box transcription factor 4; microRNA-186
Authors: Hong Xia; Vidya Bodempudi; Alexey Benyumov; Polla Hergert; Damien Tank; Jeremy Herrera; Jeff Braziunas; Ola Larsson; Matthew Parker; Daniel Rossi; Karen Smith; Mark Peterson; Andrew Limper; Jose Jessurun; John Connett; David Ingbar; Sem Phan; Peter B Bitterman; Craig A Henke Journal: Am J Pathol Date: 2014-03-13 Impact factor: 4.307
Authors: Hong Xia; Adam Gilbertsen; Jeremy Herrera; Emilian Racila; Karen Smith; Mark Peterson; Timothy Griffin; Alexey Benyumov; Libang Yang; Peter B Bitterman; Craig A Henke Journal: J Clin Invest Date: 2017-05-22 Impact factor: 14.808
Authors: Friedrich Anger; Monika Camara; Elisabeth Ellinger; Christoph-Thomas Germer; Nicolas Schlegel; Christoph Otto; Ingo Klein Journal: Stem Cells Dev Date: 2019-10-08 Impact factor: 3.272
Authors: Paul J Wolters; Timothy S Blackwell; Oliver Eickelberg; James E Loyd; Naftali Kaminski; Gisli Jenkins; Toby M Maher; Maria Molina-Molina; Paul W Noble; Ganesh Raghu; Luca Richeldi; Marvin I Schwarz; Moises Selman; Wim A Wuyts; David A Schwartz Journal: Lancet Respir Med Date: 2018-02 Impact factor: 30.700